Novel polypeptides and polynucleotides encoding same

• US 20050003370A1
• Filed: 09/07/2004
• Published: 01/06/2005
• Est. Priority Date: 10/15/1999
• Status: Abandoned Application

• Current Assignee: Raj Bandaru, Raymond J. Taupier Jr, Sudhirdas K. Prayaga
• Original Assignee: Raj Bandaru, Raymond J. Taupier Jr, Sudhirdas K. Prayaga
• Inventors: Bandaru, Raj, Prayaga, Sudhirdas K., Taupier, Raymond J. Jr.
• Application Number:
  US10/691,165
• Publication Number:
  US 20050003370A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 15/08 for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07K 14/4725 Proteoglycans, e.g. aggreccan
• CPC Class Codes: C07K 14/57581 Thymosin; Related peptides
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748

Abstract

Disclosed herein are novel human nucleic acid sequences. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving these novel nucleic acids and proteins.

Claims

1. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) a mature form of an amino acid sequence of SEQ ID NO;

5;

(b) a variant of a mature form of an amino acid sequence of SEQ ID NO;

5, wherein the said variant is 96% identical to the mature form of SEQ ID NO;

5;

(c) an amino acid sequence consisting of SEQ ID NO;

5;

(d) a variant of an amino acid sequence consisting of SEQ ID NO;

5, wherein said variant differs from the amino acid sequence of said mature form, provided that said variant is 96% identical to the amino acid sequence of SEQ ID NO;

5;

(e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising an amino acid sequence consisting of SEQ ID NO;

5 or a variant of said polypeptide, wherein the said variant is 96% identical to the amino acid sequence of SEQ I) NO;

5 or its mature form;

(f) a nucleic acid molecule comprising the complement of (a), (b), (c), (d) or (e).

2. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence of a naturally-occurring allelic nucleic acid variant.

3. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule encodes a polypeptide comprising the amino acid sequence of a naturally-occurring polypeptide variant.

4. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule differs by a single nucleotide from a nucleic acid sequence consisting of SEQ ID NO:

4.

5. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of

(a) a nucleotide sequence consisting of SEQ ID NO:

4;

(b) a nucleotide sequence differing by one or more nucleotides from a nucleotide sequence consisting of SEQ ID NO;

4 provided that no more than 20% of the nucleotides differ from said nucleotide sequence;

(c) a nucleic acid fragment of (a); and

(d) a nucleic acid fragment of (b).

6. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule hybridizes under stringent conditions to a nucleotide sequence consisting of SEQ ID NO:

4, or a complement of said nucleotide sequence.

7. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of

(a) a first nucleotide sequence comprising a coding sequence differing by one or more nucleotide sequences from a coding sequence encoding said amino acid sequence, provided that no more than 20% of the nucleotides in the coding sequence in said first nucleotide sequence differ from said coding sequence;

(b) an isolated second polynucleotide that is a complement of the first polynucleotide; and

(c) a nucleic acid fragment of (a) or (b).

8. A vector comprising the nucleic acid molecule of claim 7.

9. The vector of claim 8, further comprising a promoter operably-linked to said nucleic acid molecule.

10. A method of treating or preventing a NOV-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the nucleic acid of claim 1 in an amount sufficient to treat or prevent said NOV-associated disorder in said subject.

11. The method of claim 10, wherein said subject is a human.

12. A pharmaceutical composition comprising the nucleic acid molecule of claim 1 and a pharmaceutically-acceptable carrier.

13. A kit comprising in one or more containers, the pharmaceutical composition of claim 12.

14. The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease, the disease selected from a NOV-associated disorder, wherein said therapeutic the NOV nucleic acid of claim 1.